Lymphocytes in cancer development: Polarization towards pro-tumor immunity

Cytokine and Growth Factor Reviews

Volumn 21, Issue 1, 2010, Pages 3-10

  Ruffell, Brian ^a   DeNardo, David G ^a   Affara, Nesrine I ^a   Coussens, Lisa M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Inflammation; Lymphocytes; Tumors

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BASILIXIMAB; CD11B ANTIGEN; CD1D ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT3 PROTEIN; STAT6 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TARGETING; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HELPER CELL; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MELANOMA; METASTASIS; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SARCOMA; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR IMMUNITY; TUMOR PROMOTION; UNSPECIFIED SIDE EFFECT; VIRUS CARCINOGENESIS;

ANIMALS; CYTOKINES; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 77549085849     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2009.11.002     Document Type: Article

References (132)

1. Colotta F., Allavena P., Sica A., Garlanda C., and Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009) 1073-1081
2. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., and Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67 (2007) 9518-9527
3. De Palma M., and Coussens L.M. Immune cells and inflammatory mediators as regulators of tumor angiogenesis. In: Figg W.D., and Folkman J. (Eds). Angiogenesis: an integrative approach from science to medicine (2008), Springer, New York 225-238
4. Mantovani A., Allavena P., Sica A., and Balkwill F. Cancer-related inflammation. Nature 454 (2008) 436-444
5. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
6. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
7. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 9 (2009) 259-270
8. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9 (2009) 239-252
9. Lewis C.E., and Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 66 (2006) 605-612
10. Wilson C.B., Rowell E., and Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9 (2009) 91-105
11. Croft M., Carter L., Swain S.L., and Dutton R.W. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180 (1994) 1715-1728
12. Hamada H., Garcia-Hernandez Mde L., Reome J.B., Misra S.K., Strutt T.M., McKinstry K.K., et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182 (2009) 3469-3481
13. Lu L., and Cantor H. Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol 5 (2008) 401-406
14. Godfrey D.I., and Berzins S.P. Control points in NKT-cell development. Nat Rev Immunol 7 (2007) 505-518
15. Carding S.R., Egan P.J., and Gammadelta. T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2 (2002) 336-345
16. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
17. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 (2006) 24-37
18. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 294 (2001) 605-609
19. Daniel D., Meyer-Morse N., Bergsland E.K., Dehne K., Coussens L.M., and Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197 (2003) 1017-1028
20. Patel P., Hanson D.L., Sullivan P.S., Novak R.M., Moorman A.C., Tong T.C., et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148 (2008) 728-736
21. Boshoff C., and Weiss R. AIDS-related malignancies. Nat Rev Cancer 2 (2002) 373-382
22. Herrero J.I., Lorenzo M., Quiroga J., Sangro B., Pardo F., Rotellar F., et al. De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 11 (2005) 89-97
23. Fung J.J., Jain A., Kwak E.J., Kusne S., Dvorchik I., and Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 7 (2001) S109-S118
24. Abu-Shakra M., Buskila D., Ehrenfeld M., Conrad K., and Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60 (2001) 433-441
25. Bei R., Masuelli L., Palumbo C., Modesti M., and Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett 281 (2009) 8-23
26. Vivier E., Tomasello E., Baratin M., Walzer T., and Ugolini S. Functions of natural killer cells. Nat Immunol 9 (2008) 503-510
27. Josefowicz S.Z., and Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 30 (2009) 616-625
28. Curotto de Lafaille M.A., and Lafaille J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 30 (2009) 626-635
29. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295-307
30. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 65 (2005) 5020-5026
31. Rudensky A.Y., and Campbell D.J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 203 (2006) 489-492
32. Zhang N., Schroppel B., Lal G., Jakubzick C., Mao X., Chen D., et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 30 (2009) 458-469
33. Vignali D.A., Collison L.W., and Workman C.J. How regulatory T cells work. Nat Rev Immunol 8 (2008) 523-532
34. Tang Q., and Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9 (2008) 239-244
35. Strauss L., Bergmann C., Szczepanski M., Gooding W., Johnson J.T., and Whiteside T.L. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13 (2007) 4345-4354
36. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., and Fu Y.X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201 (2005) 779-791
37. Cao X., Cai S.F., Fehniger T.A., Song J., Collins L.I., and Piwnica-Worms D.R. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27 (2007) 635-646
38. Fujimoto S., Greene M., and Sehon A.H. Immunosuppressor T cells in tumor bearing host. Immunol Commun 4 (1975) 201-217
39. Berendt M.J., and North R.J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151 (1980) 69-80
40. Awwad M., and North R.J. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med 168 (1988) 2193-2206
41. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
42. Betts G., Twohig J., Van den Broek M., Sierro S., Godkin A., and Gallimore A. The impact of regulatory T cells on carcinogen-induced sarcogenesis. Br J Cancer 96 (2007) 1849-1854
43. Gao Q., Qiu S.J., Fan J., Zhou J., Wang X.Y., Xiao Y.S., et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25 (2007) 2586-2593
44. Hiraoka N., Onozato K., Kosuge T., and Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12 (2006) 5423-5434
45. Jordanova E.S., Gorter A., Ayachi O., Prins F., Durrant L.G., Kenter G.G., et al. Human leukocyte antigen class I. MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. Clin Cancer Res 14 (2008) 2028-2035
46. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole Jr. D.H., and Patz Jr. E.F. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 (2006) 2866-2872
47. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., and Banham A.H. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24 (2006) 5373-5380
48. Merlo A., Casalini P., Carcangiu M.L., Malventano C., Triulzi T., Menard S., et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27 (2009) 1746-1752
49. Betts G.J., Clarke S.L., Richards H.E., Godkin A.J., and Gallimore A.M. Regulating the immune response to tumours. Adv Drug Deliv Rev 58 (2006) 948-961
50. Barnett B., Kryczek I., Cheng P., Zou W., and Curiel T.J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369-377
51. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
52. Gerena-Lewis M., Crawford J., Bonomi P., Maddox A.M., Hainsworth J., McCune D.E., et al. A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. Am J Clin Oncol (2009)
53. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., and Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59 (1999) 3128-3133
54. Fong L., and Small E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26 (2008) 5275-5283
55. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., and Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
56. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8 (2008) 337-348
57. Ouyang W., Kolls J.K., and Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 (2008) 454-467
58. Bettelli E., Korn T., Oukka M., and Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 453 (2008) 1051-1057
59. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., and Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105 (2008) 15505-15510
60. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14 (2008) 3254-3261
61. Zhang B., Rong G., Wei H., Zhang M., Bi J., Ma L., et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374 (2008) 533-537
62. Zhang J.P., Yan J., Xu J., Pang X.H., Chen M.S., Li L., et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50 (2009) 980-989
63. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175 (2005) 6177-6189
64. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (2003) 2620-2627
65. Nam J.S., Terabe M., Kang M.J., Chae H., Voong N., Yang Y.A., et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68 (2008) 3915-3923
66. Xiao M., Wang C., Zhang J., Li Z., Zhao X., and Qin Z. IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 69 (2009) 2010-2017
67. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., and Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206 (2009) 1457-1464
68. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7 (2007) 41-51
69. Kortylewski M., and Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20 (2008) 228-233
70. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103 (2006) 8137-8142
71. Kryczek I., Wei S., Szeliga W., Vatan L., and Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114 (2009) 357-359
72. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112 (2008) 362-373
73. Spolski R., and Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 26 (2008) 57-79
74. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
75. Girardi M., Oppenheim D., Glusac E.J., Filler R., Balmain A., Tigelaar R.E., and Hayday A.C. Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol 122 (2004) 699-706
76. Daniel D., Chiu C., Giraud E., Inoue M., Mizzen L.A., Chu N.R., and Hanahan D. CD4+ T Cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res 65 (2005) 2018-2025
77. DeNardo D.G., Baretto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., and Coussens L.M. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16 (2009) 91-102
78. Mantovani A., Allavena P., and Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40 (2004) 1660-1667
79. Johansson M., Denardo D.G., and Coussens L.M. Polarized immune responses differentially regulate cancer development. Immunol Rev 222 (2008) 145-154
80. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
81. Street S.E., Cretney E., and Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001) 192-197
82. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., and Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95 (1998) 7556-7561
83. Street S.E., Trapani J.A., MacGregor D., and Smyth M.J. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196 (2002) 129-134
84. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191 (2000) 661-668
85. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
86. Noguchi Y., Jungbluth A., Richards E.C., and Old L.J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 93 (1996) 11798-11801
87. Nastala C.L., Edington H.D., McKinney T.G., Tahara H., Nalesnik M.A., Brunda M.J., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153 (1994) 1697-1706
88. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 (2006) 836-848
89. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198 (2003) 433-442
90. Kacha A.K., Fallarino F., Markiewicz M.A., and Gajewski T.F. Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol 165 (2000) 6024-6028
91. Ostrand-Rosenberg S., Grusby M.J., and Clements V.K. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 165 (2000) 6015-6019
92. Fallarino F., and Gajewski T.F. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 163 (1999) 4109-4113
93. Bui J.D., Carayannopoulos L.N., Lanier L.L., Yokoyama W.M., and Schreiber R.D. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 176 (2006) 905-913
94. Kemp R.A., and Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 167 (2001) 6497-6502
95. Dobrzanski M.J., Reome J.B., and Dutton R.W. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 162 (1999) 6671-6680
96. Dobrzanski M.J., Reome J.B., Hollenbaugh J.A., and Dutton R.W. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 172 (2004) 1380-1390
97. Olver S., Apte S., Baz A., and Kienzle N. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth?. Tissue Antigens 69 (2007) 293-298
98. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P., and Parish C. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197 (2003) 387-393
99. Eguchi J., Kuwashima N., Hatano M., Nishimura F., Dusak J.E., Storkus W.J., and Okada H. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol 174 (2005) 7194-7201
100. Kobayashi M., Kobayashi H., Pollard R.B., and Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160 (1998) 5869-5873
101. Wynn T.A. IL-13 effector functions. Annu Rev Immunol 21 (2003) 425-456
102. Lebel-Binay S., Laguerre B., Quintin-Colonna F., Conjeaud H., Magazin M., Miloux B., et al. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 25 (1995) 2340-2348
103. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000) 515-520
104. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198 (2003) 1741-1752
105. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4 (2004) 71-78
106. Terabe M., Park J.M., and Berzofsky J.A. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53 (2004) 79-85
107. Volpert O.V., Fong T., Koch A.E., Peterson J.D., Waltenbaugh C., Tepper R.I., and Bouck N.P. Inhibition of angiogenesis by interleukin 4. J Exp Med 188 (1998) 1039-1046
108. Schuler T., Kornig S., and Blankenstein T. Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med 198 (2003) 1487-1493
109. Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E.C., Su D., et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204 (2007) 1037-1047
110. Tupin E., Kinjo Y., and Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5 (2007) 405-417
111. Kobayashi E., Motoki K., Uchida T., Fukushima H., and Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7 (1995) 529-534
112. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
113. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278 (1997) 1623-1626
114. Crowe N.Y., Smyth M.J., and Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196 (2002) 119-127
115. Smyth M.J., Crowe N.Y., Pellicci D.G., Kyparissoudis K., Kelly J.M., Takeda K., et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99 (2002) 1259-1266
116. Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189 (1999) 1121-1128
117. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 (2003) 267-279
118. Toura I., Kawano T., Akutsu Y., Nakayama T., Ochiai T., and Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163 (1999) 2387-2391
119. Burdin N., Brossay L., and Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 29 (1999) 2014-2025
120. Fujii S., Shimizu K., Kronenberg M., and Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3 (2002) 867-874
121. Motohashi S., and Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci 99 (2008) 638-645
122. Berzofsky J.A., and Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180 (2008) 3627-3635
123. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202 (2005) 1627-1633
124. Ambrosino E., Terabe M., Halder R.C., Peng J., Takaku S., Miyake S., et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179 (2007) 5126-5136
125. Halder R.C., Aguilera C., Maricic I., and Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117 (2007) 2302-2312
126. Ostrand-Rosenberg S., Clements V.K., Terabe M., Park J.M., Berzofsky J.A., and Dissanayake S.K. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol 169 (2002) 5796-5804
127. Terabe M., Khanna C., Bose S., Melchionda F., Mendoza A., Mackall C.L., et al. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res 66 (2006) 3869-3875
128. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202 (2005) 1279-1288
129. Lee P.T., Benlagha K., Teyton L., and Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 195 (2002) 637-641
130. Gumperz J.E., Miyake S., Yamamura T., and Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195 (2002) 625-636
131. Song L., Asgharzadeh S., Salo J., Engell K., Wu H.W., Sposto R., et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest 119 (2009) 1524-1536
132. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136 (1986) 2348-2357